Contineum Therapeutics Management
Management criteria checks 2/4
Contineum Therapeutics' CEO is Carmine Stengone, appointed in Oct 2018, has a tenure of 6.08 years. total yearly compensation is $2.32M, comprised of 22.3% salary and 77.7% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $178.37K. The average tenure of the management team and the board of directors is 4.1 years and 2.8 years respectively.
Key information
Carmine Stengone
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 22.3% |
| CEO tenure | 6.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 4.1yrs |
| Board average tenure | 2.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$29m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$447k |
| Dec 31 2023 | US$2m | US$516k | US$3m |
Compensation vs Market: Carmine's total compensation ($USD2.32M) is about average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Insufficient data to compare Carmine's compensation with company performance.
CEO
Carmine Stengone (48 yo)
6.1yrs
Tenure
US$2,315,299
Compensation
Mr. Carmine N. Stengone, MS, MBA, serves as Chief Executive Officer, President & Director of Contineum Therapeutics, Inc. since October 2018 and served as its Chairman of the Board until March 2024. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$2.32m | 0.045% $ 178.4k | |
| Chief Financial Officer | 4.1yrs | US$1.03m | 0% $ 0 | |
| Chief Science Officer | 6.7yrs | US$1.79m | 0.67% $ 2.7m | |
| Senior Manager of Accounting | less than a year | no data | no data | |
| General Counsel & Corporate Secretary | less than a year | no data | no data | |
| Chief Medical Officer & Senior VP of Clinical Development | 4.8yrs | no data | 0.050% $ 196.6k | |
| Senior VP & Head of Research | no data | no data | no data | |
| Senior Director & Corporate Controller | 3.6yrs | no data | no data |
4.1yrs
Average Tenure
52yo
Average Age
Experienced Management: CTNM's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$2.32m | 0.045% $ 178.4k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Clinical Advisor | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman of the Board | 2.8yrs | US$23.82k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$25.00k | 0% $ 0 | |
| Independent Director | 5yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Board: CTNM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.